RGD Reference Report - Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. - Rat Genome Database

RGD Reference Report - Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

General

Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk.
Authors:	Ahn, ER Lander, G Jy, W Bidot, CJ Jimenez, JJ Horstman, LL Ahn, YS
Citation:	Ahn ER, etal., Thromb Res. 2004;114(2):143-8.
RGD ID:	11352250
Pubmed:	PMID:15306157 (View Abstract at PubMed)
DOI:	DOI:10.1016/j.thromres.2004.06.005 (Journal Full-text)
INTRODUCTION: Soluble CD40L (sCD40L) ELISA has emerged as a promising predictor of poor outcomes in acute coronary syndrome. Yet many blood processing techniques have been used with little consideration of their effect on the results. METHODS: We measured sCD40L by ELISA in 10 patients with thrombocytopenia and 12 with normal or high platelet counts and 8 healthy controls using three sampling techniques: serum clotted on ice (serum-I) or at room temperature (serum-RT) and platelet poor plasma (PPP). RESULTS: Serum-RT samples, compared to serum-I, gave significantly higher CD40L values (p=0.003), demonstrating that ex vivo sCD40L release by activated platelets is inhibited by cold temperature. Although serum-I and PPP were comparable in patients with normal platelet counts, serum-I gave significantly higher values than PPP in the thrombocytosis group (p=0.01), suggesting that cold inhibition is insufficient in the latter group. To estimate the fraction of sCD40L that was microparticle-bound CD40L (mp-CD40L), 16 samples underwent 0.1-microm filtration. 50.6% of sCD40L was mp-CD40L in serum-RT, whereas 21.3% and 29.9% were observed in serum-I and PPP, respectively. Lastly, plasma sCD40L was assayed in 46 patients with and 35 without thrombosis. Plasma sCD40L did not correlate with platelet count in non-thrombotic, non-inflammatory patients but did (p<0.01) in those with thrombosis. CONCLUSIONS: Sample processing and temperature profoundly affect sCD40L assay. Serum-I and PPP minimize the release of sCD40L ex vivo and better represent sCD40L in vivo. However, PPP may be preferable particularly in patients with thrombocytosis. The existence of mp-CD40L highlights the importance of centrifuge conditions.

Only show annotations with direct experimental evidence (0 objects hidden)

Object Symbol	Species	Term	Qualifier	Evidence	With	Notes	Source	Original Reference(s)
CD40LG	Human	thrombosis	susceptibility	IEP		protein:increased expression:plasma (human)	RGD
Cd40lg	Rat	thrombosis	susceptibility	ISO	RGD:1352959	protein:increased expression:plasma (human)	RGD
Cd40lg	Mouse	thrombosis	susceptibility	ISO	RGD:1352959	protein:increased expression:plasma (human)	RGD

Genes (Rattus norvegicus)


Cd40lg (CD40 ligand)

Genes (Mus musculus)


Cd40lg (CD40 ligand)

Genes (Homo sapiens)


CD40LG (CD40 ligand)